NAA Services for Anti-Zonulin Antibodies

Creative Biolabs has established a universal platform for natural autoantibody (NAA) services. With years of experience and professional technology, now we can provide anti-zonulin antibody marker services for diseases diagnosis and therapeutic monitoring for celiac disease (CD). Moreover, more NAA detection and profiling services can be found on our web pages.

Background of Anti-zonulin Antibodies

Zonulin is the precursor of haptoglobin 2 protein that regulates the permeability of tight junctions between cells in the wall of the digestive tract. Zonulin could be useful as a serum marker for non-celiac gluten sensitivity. It was initially discovered in 2000 by Alessio Fasano and his team at the University of Maryland. It is an analogue of zonula occludens toxin, secreted by cholera pathogen Vibrio cholerae. Zonulin has been proven to be involved in the pathogenesis of coeliac disease and diabetes mellitus type 1. Gliadin is a kind of glycoprotein existing in wheat, which can activate zonulin signaling irrespective of the genetic expression of autoimmunity, thus causing increased intestinal permeability to macromolecules. Zonulin expression is raised in intestinal tissues during the acute phase of coeliac disease along with the production of anti-zonulin autoantibodies, and the titer of the anti-zonulin antibody is consistent with the acute phase of coeliac disease.

The Role of Anti-zonulin Antibodies in Celiac Disease

Celiac disease (CD) is a T-cell-mediated, autoimmune inflammatory disorder, commonly caused by an improper immune response to ingested gluten proteins in genetically susceptible people. Characterized by intestinal malabsorption associated with villous atrophy, crypt hyperplasia and lymphocytic infiltration of the small intestinal mucosa, the disease is improved after a gluten-free diet. In addition, CD is also associated with various extraintestinal syndromes, including neurologic complications such as neuropathy, ataxia, seizures, and neurobehavioral changes. During the acute phase of coeliac disease, the zonulin expression was raised in intestinal tissues along with the production of anti-zonulin autoantibodies. Although the anti-zonulin IgG was not higher in patients with CD than controls, in contrast, anti-zonulin IgA was raised in the serum samples of patients with CD. The incidence of anti-zonulin autoantibodies during the acute phase of coeliac disease is consistent with the incidence of other autoantibodies described in CD. In remission, the anti-zonulin IgA levels and intestinal permeability can return to normal after 3-6 months on a gluten-free diet, further evidence found that zonulin is the main contributor to disrupted barrier function.

Fig.1 Intestinal epithelial damage in celiac disease. (Ferretti, et al., 2012)Fig.1 Intestinal epithelial damage in celiac disease.1

What Can We Do about NAA?

We provide a full range of NAA services with first-rate technology platforms and prominent scientists to cover every step of customers’ program, from NAA detection and profiling to NAA epitope mapping and paratope mapping. In addition, a wide range of NAA products is also available for your choice.

Features of Our Services

Equipped with world-leading technology platforms and professional scientific staff, Creative Biolabs is always dedicated to assisting our clients with the most satisfactory NAA services to promote all kinds of disease diagnosis and treatment. If you are interested in our service, please feel free to contact us for more details.

Reference:

  1. Ferretti, Gianna, et al. "Celiac disease, inflammation and oxidative damage: a nutrigenetic approach." Nutrients 4.4 (2012): 243-257.
For Research Use Only | Not For Clinical Use

Related Services:

Products:

Resource:

Applications:

Online Inquiry
Inquiry